Olin Corporation manufactures and distributes chemical products in the United States, Europe, Asia Pacific, Latin America, and Canada. It operates through three segments: Chlor Alkali Products and Vinyls; Epoxy; and Winchester. The Chlor Alkali Products and Vinyls segment offers chlorine and caustic soda, ethylene dichloride and vinyl chloride monomers, methyl chloride, methylene chloride, chloroform, carbon tetrachloride, perchloroethylene, hydrochloric acid, hydrogen, bleach products, potassium hydroxide, and chlorinated organics intermediates and solvents. The Epoxy segment provides Allylics, such as allyl chloride, epichlorohydrin, and glycerin; aromatics, including acetone, bisphenol, cumene, and phenol; liquid and solid epoxy resins; and converted epoxy resins and additives. The Winchester segment offers sporting ammunition products, including shotshells, small caliber centerfire, and rimfire ammunition products for hunters and recreational shooters, and law enforcement agencies; small caliber military ammunition products for use in infantry and mounted weapons; and industrial products comprising gauge loads and powder-actuated tool loads for maintenance applications in power and concrete industries, and powder-actuated tools in construction industry. The company markets its products through its sales force, as well as directly to various industrial customers, mass merchants, retailers, wholesalers, gun clubs, other distributors, and the U.S. Government and its prime contractors. Olin Corporation was incorporated in 1892 and is based in Clayton, Missouri.

Olin Corporation

The latest announcement is out from Molecular Partners ( ($MOLN) ). On July 16, 2026, Molecular Partners announced the first patients have been dos...

Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Molecular Partners today and set a price target of $12.00. According to TipRanks, Zh...

LifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)

Pollen Street Group Limited ( ($GB:POLN) ) has provided an update. Pollen Street Group Limited disclosed that Michael England, a person discharging...

Pollen Street Reports Internal Transfer of PDMR Shareholding

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edgewise Therapeutics (EWTX), Molecular Partners (MO...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY), Molecular Partners (MOLN) a...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Molecular Partners (MOLN) and Exelixis (EXEL)

Analysts are intrested in these 5 stocks: ( ($STNG) ), ( ($OLN) ), ( ($CMCSA) ), ( ($KTOS) ) and ( ($SPCX) ). Here is a breakdown of their recent


Scorpio, Olin, Comcast, Kratos, SpaceX Trending With Analysts

Wells Fargo analyst Michael Sison maintained a Buy rating on Olin yesterday and set a price target of $25.00. The company’s shares closed yesterday...

Wells Fargo Remains a Buy on Olin (OLN)

Molecular Partners ( ($MOLN) ) has provided an announcement. On July 2, 2026, Molecular Partners and Orano Med reported that the first patients hav...

Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial

The latest update is out from Pollen Street Group Limited ( ($GB:POLN) ). Pollen Street Group Limited has updated the market on its total voting ri...

Pollen Street Group Updates Market on Total Voting Rights

Pollen Street Group Limited ( ($GB:POLN) ) has issued an announcement. Pollen Street Group Limited disclosed that its Chief Financial Officer, Cris...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OLN	$22.35	-3.66%	276.04K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OLN	$22.35	-3.7%	276.04K
3
4
5
6

OLN

OLN

Get Olin Corporation Data in Excel

Get Olin Corporation Data in Excel